Gastroenterol Res

Gastroenterology Research, ISSN 1918-2805 print, 1918-2813 online, Open Access

Article copyright, the authors; Journal compilation copyright, Gastroenterol Res and Elmer Press Inc

Journal website http://www.gastrores.org

Original Article

Volume 11, Number 6, December 2018, pages 397-403

Long-Term Safety and Efficacy of Fecal Microbiota Transplantation in the Treatment of Clostridium difficile Infection in Patients With and Without Inflammatory Bowel Disease: A Tertiary Care Center’s Experience

**Table 1.** Characteristics of Patients With and Without IBD
	IBD (n = 21)	Non-IBD (n = 57)
*P < 0.05. FMT: fecal microbiota transplant; CLN: colonoscopy; TI: terminal ileum; G/J: gastrostomy and/or jejunostomy.
Age in years, mean (SD)	47.6 (20.7)*	61.2 (19.3)*
Gender n (%)
Female	9 (42.9)*	45 (79.0)*
Male	12 (57.1)*	12 (21.1)*
FMT settings n (%)
Inpatient	4 (19.1)	6 (10.5)
Outpatient	17 (81.0)	51 (89.5)
Abdominal pain n (%)	15 (71.4)*	26 (45.6)*
Severity of diarrhea n (%)
Mild	0 (0.0)	7 (12.3)
Moderate	15 (71.4)	38 (66.7)
Severe	6 (28.6)	12 (21.1)
Source of stool n (%)
First degree relative	7 (33.3)	21 (36.8)
OpenBiome	13 (61.9)	34 (59.7)
Friend	1 (4.8)	1 (1.8)
Med student	0 (0.0)	1 (1.8)
Method of delivery n (%)
CLN to TI	18 (85.7)	44 (77.2)
CLN to cecum	1 (4.8)	5 (8.8)
Throughout colon	0 (0.0)	1 (1.8)
Flex sigmoidoscopy	1 (4.8)	2 (3.5)
Enema	0 (0.0)	1 (1.8)
G/J tube	0 (0.0)	2 (3.5)
Enteroscopy to jejunum	0 (0.0)	1 (1.8)
Antibiotics used n (%)
PO metronidazole	15 (71.4)	40 (70.2)
PO vancomycin	21 (100.0)	52 (91.2)
IV vancomycin	3 (14.3)	5 (8.8)
Fidaxomycin	7 (33.3)	15 (26.3)

Table 1. Characteristics of Patients With and Without IBD

IBD (n = 21)

Non-IBD (n = 57)

*P < 0.05. FMT: fecal microbiota transplant; CLN: colonoscopy; TI: terminal ileum; G/J: gastrostomy and/or jejunostomy.

Age in years, mean (SD)

47.6 (20.7)*

61.2 (19.3)*

Gender n (%)

Female

9 (42.9)*

45 (79.0)*

Male

12 (57.1)*

12 (21.1)*

FMT settings n (%)

Inpatient

4 (19.1)

6 (10.5)

Outpatient

17 (81.0)

51 (89.5)

Abdominal pain n (%)

15 (71.4)*

26 (45.6)*

Severity of diarrhea n (%)

Mild

0 (0.0)

7 (12.3)

Moderate

15 (71.4)

38 (66.7)

Severe

6 (28.6)

12 (21.1)

Source of stool n (%)

First degree relative

7 (33.3)

21 (36.8)

OpenBiome

13 (61.9)

34 (59.7)

Friend

1 (4.8)

1 (1.8)

Med student

0 (0.0)

1 (1.8)

Method of delivery n (%)

CLN to TI

18 (85.7)

44 (77.2)

CLN to cecum

1 (4.8)

5 (8.8)

Throughout colon

0 (0.0)

1 (1.8)

Flex sigmoidoscopy

1 (4.8)

2 (3.5)

Enema

0 (0.0)

1 (1.8)

G/J tube

0 (0.0)

2 (3.5)

Enteroscopy to jejunum

0 (0.0)

1 (1.8)

Antibiotics used n (%)

PO metronidazole

15 (71.4)

40 (70.2)

PO vancomycin

21 (100.0)

52 (91.2)

IV vancomycin

3 (14.3)

5 (8.8)

Fidaxomycin

7 (33.3)

15 (26.3)

**Table 2.** Comparison of Patients With IBD vs. Non-IBD
	IBD (n = 21)	Non-IBD (n = 57)	Total
Primary cure	15 (71.4%)	45 (78.9%)	60 (76.9%)
Secondary cure	21 (100%)	57 (100%)	78 (100%)
Early recurrence	2 (9.5%)	6 (10.5%)	8 (10.25%)
Late recurrence	4 (19.0%)	6 (10.5%)	10 (12.8%)
Repeat FMT	4 (57.1%)	3 (42.8%)	7 (8.9%)

Table 2. Comparison of Patients With IBD vs. Non-IBD

IBD (n = 21)

Non-IBD (n = 57)

Total

Primary cure

15 (71.4%)

45 (78.9%)

60 (76.9%)

Secondary cure

21 (100%)

57 (100%)

78 (100%)

Early recurrence

2 (9.5%)

6 (10.5%)

8 (10.25%)

Late recurrence

4 (19.0%)

6 (10.5%)

10 (12.8%)

Repeat FMT

4 (57.1%)

3 (42.8%)

7 (8.9%)

**Table 3.** Complications After FMT in IBD Patients by Recurrence of CDI
	Recurrence (n = 6)	No recurrence (n = 15)	All IBD patients (n = 21)
Colectomy	1 (16.7)	1 (6.7)	2 ( 9.5)
Hospitalizations for IBD flare	1 (16.7)	4 (26.7)	5 (23.8)
Ileal resection	1 (16.7)	0 (0.0)	1 (4.7)
None	3 (50.0)	10 (66.7)	13 (61.9)

Table 3. Complications After FMT in IBD Patients by Recurrence of CDI

Recurrence (n = 6)

No recurrence (n = 15)

All IBD patients (n = 21)

Colectomy

1 (16.7)

1 (6.7)

2 ( 9.5)

Hospitalizations for IBD flare

1 (16.7)

4 (26.7)

5 (23.8)

Ileal resection

1 (16.7)

0 (0.0)

1 (4.7)

None

3 (50.0)

10 (66.7)

13 (61.9)